BMS
Forxiga approved in European Union
November 15, 2012Sales and Marketing AstraZeneca, BMS, Forxiga, diabetes
AstraZeneca and Bristol-Myers Squibb’s first-in-class type II diabetes treatment Forxiga has been approved in Europe – a major filip for …
NICE hails ‘breakthrough’ skin cancer treatments
November 2, 2012Sales and Marketing BMS, NICE, Roche, Yervoy, Zelboraf
Two new skin cancer drugs have been recommended by NICE, which hailed the drugs as ‘breakthrough treatments’. Bristol-Myers Squibb’s Yervoy …
Patent losses force change for Sanofi
October 3, 2012Sales and Marketing Avapro, BMS, Plavix, Sanofi, patent loss
Patent expiries are behind the decision by Sanofi and Bristol-Myers Squibb to radically restructure their long-term corporate alliance. The loss …
BMS highlights Yervoy survival data
October 1, 2012Research and Development, Sales and Marketing BMS, Roche, Yervoy, Zelboraf
Bristol-Myers Squibb’s melanoma drug Yervoy helps patients survive for longer than if they are receiving standard chemotherapy alone, according to …
Eliquis receives nod in AF
September 24, 2012Sales and Marketing BMS, CHMP, Eliquis, Pfizer, Pradaxa, Xarelto
Bristol-Myers Squibb and Pfizer have received a boost with the CHMP’s recommendation that their co-marketed oral anticoagulant Eliquis should gain …
Patient death halts BMS hep C trial
August 30, 2012Sales and Marketing BMS, HCV, hepatitis C
Bristol-Myers Squibb has admitted that the death of a patient was behind its decision to stop development of a potential …
NICE still minded not to recommend Zelboraf
August 9, 2012Sales and Marketing BMS, NICE, QALY, Yervoy, Zelboraf
NICE is asking Roche for more information about its melanoma pill Zelboraf, saying it is still too expensive and its …
Bristol-Myers Squibb halts Hep C pill study
August 2, 2012Research and Development, Sales and Marketing BMS, hepatitis C, pill, trial suspension
Bristol-Myers Squibb has halted a mid-stage trial of a new Hepatitis C drug due to major safety concerns. In a …
BMS unveils $165m expansion in Puerto Rico
July 17, 2012Manufacturing and Production BMS, Puerto Rico, diabetes, manufacturing
A facility operated by Bristol-Myers Squibb in Puerto Rico stands to benefit from a $165 million investment programme that will …
AstraZeneca and BMS buy Amylin for $7 billion
July 2, 2012Sales and Marketing Amylin, AstraZeneca, BMS
AstraZeneca and Bristol-Myers Squibb have struck a deal to purchase diabetes specialist Amylin in a complicated agreement worth $7 billion. …
FDA delays Eliquis approval
June 26, 2012Sales and Marketing BMS, Eliquis, FDA, Pfizer, Xarelto
The FDA has asked Pfizer and Bristol-Myers Squibb for more information about its key blood thinner Eliquis. The US regulator …
BMS invests $15 million in Asian diabetes programme
June 11, 2012Sales and Marketing Asia, BMS, China, India, Onglyza, diabetes
Bristol-Myers Squibb has invested $15 million into its ‘Together on Diabetes’ campaign in India and China. Together on Diabetes is …
Plavix loses US patent protection
May 18, 2012Sales and Marketing BMS, FDA, Lipitor, Pfizer, Plavix, Sanofi
Sanofi and Bristol-Myers Squibb’s blood thinner Plavix has lost its patent protection in the US. The drug, which made $6.6 …
Scottish watchdog rejects Yervoy
May 14, 2012Sales and Marketing BMS, Cancer, NICE, SMC, Yervoy, melanoma
The Scottish Medicines Consortium is not recommending Bristol-Myers Squibb’s melanoma treatment Yervoy. The SMC said that Yervoy (ipilimumab), which has …
New Quad HIV pill on track for FDA approval
May 14, 2012Research and Development, Sales and Marketing BMS, Compera, FDA, Gilead, HIV, The Quad
Gilead Sciences’ four-in-one HIV pill has been given the thumbs up by an FDA advisory group. The US regulator is …
